Existing therapeutic strategies for managing Parkinson disease (PD), which focus on
addressing the loss of dopamine and dopaminergic function linked with degeneration of …

Parkinson's disease (PD) is a common neurodegenerative disease typified by a movement
disorder consisting of bradykinesia, rest tremor, rigidity, and postural instability. Treatment …

Parkinson's disease (PD) is the second more common neurodegenerative disease with
increasing incidence worldwide associated to the population ageing. Despite increasing …

Parkinson's disease (PD) is a neurodegenerative disorder pathologically distinguished by
degeneration of dopaminergic neurons in the substantia nigra pars compacta. Muscle …

Abstracts Parkinson's disease (PD) is the second most common progressive
neurodegenerative disease worldwide. However, there is no available therapy reversing the …

Parkinson's Disease (PD) is the second most common neurodegenerative disorder. Clinical
approaches to manage PD include symptomatic therapies, serving to compensate for the …

Parkinson disease is an inexorably progressive neurodegenerative disorder. Multiple
attempts have been made to establish therapies for Parkinson disease which provide …

Parkinson's disease (PD) is the second-leading cause of dementia and is characterized by a
progressive loss of dopaminergic neurons in the substantia nigra alongside the presence of …

Parkinson׳ s disease (PD) is chronic progressive neurodegenerative disorder characterized
by profound loss of dopaminergic neurons in the nigrostriatal pathway. It is recognized by …

Since the 1960's treatments for Parkinson's disease (PD) have traditionally been directed to
restore or replace dopamine, with L-Dopa being the gold standard. However, chronic L …